- Home
- TSE vs PRLD Comparison
TSE vs PRLD Comparison
Compare TSE & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSE
- PRLD
- Stock Information
- Founded
- TSE 2010
- PRLD 2016
- Country
- TSE United States
- PRLD United States
- Employees
- TSE N/A
- PRLD N/A
- Industry
- TSE Major Chemicals
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- TSE Industrials
- PRLD Health Care
- Exchange
- TSE Nasdaq
- PRLD Nasdaq
- Market Cap
- TSE 68.0M
- PRLD 69.1M
- IPO Year
- TSE 2014
- PRLD 2020
- Fundamental
- Price
- TSE $0.79
- PRLD $1.65
- Analyst Decision
- TSE
- PRLD Strong Buy
- Analyst Count
- TSE 0
- PRLD 3
- Target Price
- TSE N/A
- PRLD $4.00
- AVG Volume (30 Days)
- TSE 494.9K
- PRLD 3.6M
- Earning Date
- TSE 11-06-2025
- PRLD 11-12-2025
- Dividend Yield
- TSE 3.81%
- PRLD N/A
- EPS Growth
- TSE N/A
- PRLD N/A
- EPS
- TSE N/A
- PRLD N/A
- Revenue
- TSE $3,133,800,000.00
- PRLD $10,500,000.00
- Revenue This Year
- TSE N/A
- PRLD N/A
- Revenue Next Year
- TSE $5.20
- PRLD N/A
- P/E Ratio
- TSE N/A
- PRLD N/A
- Revenue Growth
- TSE N/A
- PRLD 250.00
- 52 Week Low
- TSE $0.76
- PRLD $0.61
- 52 Week High
- TSE $6.85
- PRLD $4.22
- Technical
- Relative Strength Index (RSI)
- TSE 19.69
- PRLD 52.10
- Support Level
- TSE $1.15
- PRLD $1.17
- Resistance Level
- TSE $1.32
- PRLD $1.73
- Average True Range (ATR)
- TSE 0.13
- PRLD 0.39
- MACD
- TSE -0.03
- PRLD -0.01
- Stochastic Oscillator
- TSE 3.05
- PRLD 16.31
About TSE Trinseo PLC
Trinseo PLC is a materials company and manufacturer of latex and plastics products. The company's operating segments include Latex Binders, Americas Styrenics, Engineered Materials, and Polymer Solutions. Maximum revenue is generated from its Polymer Solutions segment, which consists of various polymers, the majority of which are for automotive, building, and construction applications. The product offerings of this segment include ABS, styrene-acrylonitrile, polystyrene, and polycarbonate products, which are marketed through brands like Magnum and Styron. Geographically, the company generates maximum revenue from Europe, followed by the United States, Asia-Pacific, and the Rest of the world.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.